FDA Issues Draft Guidance on Responding to Form 483 Observations
In March 2026, the U.S. Food and Drug Administration (FDA or the Agency) issued the draft guidance for industry, Responding to FDA Form 483 Observations at the Conclusion of a Drug CGMP Inspection. The draft guidance provides FDA’s current approach on how human and animal drug manufacturers should structure and submit written responses to FDA Form 483 observ
News & Perspectives4mo ago 
